Últimas noticias sobre Viking Therapeutics (NASDAQ:VKTX) Bolsa

Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

BLDR

SERV

VKTX

VRTX

Jim Cramer analiza VRTX, SERV, BLDR y VKTX en &#39;Mad Money&#39;. Descubre por qué algunas acciones suben mientras otras caen.

Jim Cramer analiza las mejores oportunidades de inversión en &#39;Mad Money&#39;

Viking Therapeutics Inc

WIIM

AMGN

GILD

IONS

Shares of pharmaceutical and healthcare stocks are trading lower. The sector has been under pressure after president-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 50%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $521,480, and 7 are calls, for a total amount of $238,153.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $100.0 for Viking Therapeutics, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 344.29 with a total volume of 1,535.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $40.0 to $100.0 over the last 30 days.
<h3>Viking Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731690085_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$22.3</td>
<td>$22.1</td>
<td>$22.2</td>
<td>$67.50</td>
<td>$288.6K</td>
<td align="right">73</td>
<td align="right">138</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.4</td>
<td>$3.3</td>
<td>$3.4</td>
<td>$100.00</td>
<td>$68.0K</td>
<td align="right">545</td>
<td align="right">207</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$20.1</td>
<td>$16.5</td>
<td>$18.95</td>
<td>$70.00</td>
<td>$56.8K</td>
<td align="right">83</td>
<td align="right">30</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$33.9</td>
<td>$32.4</td>
<td>$33.08</td>
<td>$75.00</td>
<td>$52.9K</td>
<td align="right">373</td>
<td align="right">16</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$5.2</td>
<td>$4.8</td>
<td>$4.92</td>
<td>$55.00</td>
<td>$34.4K</td>
<td align="right">155</td>
<td align="right">152</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Viking Therapeutics's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,854,236, the VKTX's price is down by -4.56%, now at $51.13. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>Expert Opinions on Viking Therapeutics</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $96.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $90. 
&#x2A; Consistent in their evaluation, an analyst from HC Wainwright &amp; Co. keeps a Buy rating on Viking Therapeutics with a target price of $102. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Market Whales and Their Recent Bets on VKTX Options

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$87.00</td>
<td>$27.8K</td>
<td>600</td>
<td>3.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$70.00</td>
<td>$71.9K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.00</td>
<td>$41.8K</td>
<td>250</td>
<td>926</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$320.00</td>
<td>$376.7K</td>
<td>1.6K</td>
<td>760</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$65.00</td>
<td>$645.0K</td>
<td>1</td>
<td>750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$55.00</td>
<td>$112.1K</td>
<td>1.7K</td>
<td>726</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>445</td>
<td>431</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$23.00</td>
<td>$95.7K</td>
<td>4.2K</td>
<td>288</td>
</tr>
<tr>
<td>PTGX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$38.1K</td>
<td>48</td>
<td>268</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$35.5K</td>
<td>1.1K</td>
<td>157</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be neutral, expiring in 9 day(s) on November 22, 2024. This event was a transfer of 316 contract(s) at a $87.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $88.0 per contract. There were 600 open contracts at this strike prior to today, and today 3045 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on November 29, 2024. This event was a transfer of 899 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $71.9K, with a price of $80.0 per contract. There were 2173 open contracts at this strike prior to today, and today 1039 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 416 contract(s) at a $11.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.8K, with a price of $100.0 per contract. There were 250 open contracts at this strike prior to today, and today 926 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on December 20, 2024. Parties traded 352 contract(s) at a $320.00 strike. This particular call needed to be split into 46 different trades to become filled. The total cost received by the writing party (or parties) was $376.7K, with a price of $1070.0 per contract. There were 1630 open contracts at this strike prior to today, and today 760 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bullish sentiment. It expires in 275 day(s) on August 15, 2025. Parties traded 750 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $645.0K, with a price of $860.0 per contract. There were 1 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 210 contract(s) at a $55.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $112.1K, with a price of $533.0 per contract. There were 1798 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 85 contract(s) at a $100.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $59.3K, with a price of $695.0 per contract. There were 445 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on November 15, 2024. Parties traded 174 contract(s) at a $23.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $95.7K, with a price of $549.0 per contract. There were 4250 open contracts at this strike prior to today, and today 288 contract(s) were bought and sold. 
• For PTGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), we notice a call option sweep that happens to be bearish, expiring in 65 day(s) on January 17, 2025. This event was a transfer of 37 contract(s) at a $35.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $1030.0 per contract. There were 48 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 25 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $35.5K, with a price of $1416.0 per contract. There were 1186 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INCY

PTGX

10 Health Care Stocks With Whale Alerts In Today's Session

Biotech

News

General

Viking Therapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and raises the price target from $90 to $102.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Viking Therapeutics, Raises Price Target to $102

Viking Therapeutics shares are trading lower. The company revealed weight loss results from its oral obesity drug FK2735 at ObesityWeek 2024.

<ul>
<li>DJT</li>
<li>NVDA</li>
<li>VKTX</li>
<li>TSLA</li>
<li>SMCI</li>
<li>LOT</li>
<li>AMD</li>
<li>PLTR</li>
<li>META</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 4, 2024 (Via Swaggy Stocks)

Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) announced that new clinical data from the company&#8217;s VK2735 obesity program were highlighted in two poster presentations <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41708958/viking-therapeutics-reports-new-data-from-vk2735-obesity-program-at-obesityweek-2024" rel="noreferrer noopener">at ObesityWeek&nbsp;2024</a>.
Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.
Highlights from one poster presentation include new data from the Phase 1 multiple ascending dose (MAD) trial of an oral tablet formulation of VK2735 dosed daily for 28 days, including results for the study&#8217;s 60 mg, 80 mg, and 100 mg <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37937068/viking-therapeutics-investigational-oral-obesity-drug-shows-reduced-weight-in-small-study" rel="noreferrer noopener">daily treatment cohorts</a>.&nbsp;
Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2%.
Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%.
At follow-up visits through Day 57, persistent weight loss effects were observed, ranging up to 8.3% from baseline four weeks after the last dose of VK2735 was administered.
An exploratory assessment of the proportion of subjects achieving at least 5% weight loss after 28 days demonstrated that up to 100% of VK2735-treated subjects achieved ≥5% weight loss, compared with 0% for placebo.
A second poster presentation highlights follow-up results from the company&#8217;s Phase 2 VENTURE trial of VK2735.
As previously reported, patients receiving weekly doses of VK2735 demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 14.7% from baseline.
Statistically significant differences compared to baseline and placebo were observed for all doses starting at Week One and continuing throughout the 13-week treatment period.
Reductions in body weight were progressive throughout the study, with no plateau observed for weight loss at 13 weeks. In addition, up to 88% of patients in VK2735 treatment groups achieved ≥10% weight loss, compared with 4% for placebo.
The results also showed that all cohorts receiving VK2735 maintained most of their weight loss four weeks after receiving the final dose of VK2735 in the study.&nbsp;
An exploratory analysis of changes in diabetes status was also performed, demonstrating that treatment with VK2735 increased the odds of patients with prediabetic status at baseline shifting to normoglycemic (non-diabetic) status over the 13-week treatment period.
Similarly, the proportion of patients with normal glycemic status at baseline transitioning to prediabetic status favored VK2735, with approximately 31% of placebo patients transitioning to prediabetic status, compared with 2% among patients receiving VK2735.
Oral VK2735 continued to demonstrate encouraging safety and tolerability following 28 days of once-daily dosing at doses up to and including 100 mg.
Price Action: VKTX stock is up 5.65% at $77.00 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41710716/exclusive-janover-scores-new-deal-with-real-estate-firm-for-ai-client-engagement-tools" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Janover Scores New Deal With Real Estate Firm For AI Client Engagement Tools</a></li>
</ul>

Equities

Health Care

Movers

Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety

Viking Therapeutics, Inc. ("Viking") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek&#xAE; 2024, the annual meeting of the Obesity Society.&nbsp; VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders.&nbsp; Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.
&nbsp;
Highlights from one poster presentation include new data from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 dosed daily for 28 days, including results for the study's 60 mg, 80 mg, and 100 mg daily treatment cohorts.&nbsp; A second poster presentation highlights follow-up results from the company's Phase 2 VENTURE clinical trial of VK2735 demonstrating the treatment's longer-term maintenance effects and pharmacokinetic information.
Poster Presentation #017: First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults
Poster #017 presented updated data from the previously reported 28-day MAD study of the oral tablet formulation of VK2735, including new results from cohorts dosed at 60 mg, 80 mg, and 100 mg daily.&nbsp; These results continued to show positive signs of clinical activity over the 28-day treatment period in this study. &nbsp;Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2%. &nbsp;Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%. &nbsp;Persistent weight loss effects were observed at follow-up visits through Day 57, ranging up to 8.3% from baseline, four weeks after the last dose of VK2735 was administered.&nbsp; An exploratory assessment of the proportion of subjects achieving at least 5% weight loss after 28 days demonstrated that up to 100% of VK2735-treated subjects achieved ≥5% weight loss, compared with 0% for placebo. &nbsp;Based on a preliminary evaluation of weight loss trajectories at multiple dose levels, the company believes that continued treatment beyond 28 days may provide further reductions in body weight.

Viking Therapeutics' VK2735 Shows Weight Loss Results at ObesityWeek® 2024

<a href="https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/">https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/</a>
All doses of Novo Nordisk&#39;s blockbuster diabetes and obesity treatments are <a href="https://dps.fda.gov/drugshortages/activeingredient/semaglutide-injection">listed as available</a> on the Food and Drug Administration&#39;s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
Semaglutide, the scientific name for Novo&#39;s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times. With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward.
Over the past two years, patients seeking treatment have been turning to compounding pharmacies, which make cheaper copies of branded treatments and are legally allowed to do so only when the branded treatments are listed on the FDA&#39;s shortage list.&nbsp;

&nbsp;

DRIO

RHHBY

TERN

VANI

Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA; It remains unclear how the update could affect patients as well as compounders' - STAT News

Financial giants have made a conspicuous bearish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) revealed 34 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $146,300, and 29 were calls, valued at $2,404,204.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $105.0 for Viking Therapeutics over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $15.0 to $105.0 in the last 30 days. 
<h3>Viking Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730232049_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.0</td>
<td>$8.6</td>
<td>$8.9</td>
<td>$75.00</td>
<td>$213.6K</td>
<td style="text-align: right;">745</td>
<td style="text-align: right;">252</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.9</td>
<td>$59.0</td>
<td>$61.34</td>
<td>$15.00</td>
<td>$191.7K</td>
<td style="text-align: right;">154</td>
<td style="text-align: right;">31</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$8.1</td>
<td>$7.5</td>
<td>$7.8</td>
<td>$77.50</td>
<td>$187.2K</td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">493</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$25.5</td>
<td>$25.3</td>
<td>$25.5</td>
<td>$50.00</td>
<td>$127.5K</td>
<td style="text-align: right;">863</td>
<td style="text-align: right;">360</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$25.5</td>
<td>$25.4</td>
<td>$25.4</td>
<td>$50.00</td>
<td>$127.0K</td>
<td style="text-align: right;">863</td>
<td style="text-align: right;">310</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Following our analysis of the options activities associated with Viking Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Viking Therapeutics</h3>
<ul>
<li>Currently trading with a volume of 2,977,355, the VKTX's price is down by -1.41%, now at $73.47. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 99 days.</li>
</ul>
<h3>Professional Analyst Ratings for Viking Therapeutics</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $90.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $90. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $90.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Viking Therapeutics

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) has outperformed the market over the past 5 years by 49.88% on an annualized basis producing an average annual return of 63.6%. Currently, Viking Therapeutics has a market capitalization of $8.80 billion. 
Buying $100 In VKTX: If an investor had bought $100 of VKTX stock 5 years ago, it would be worth $1,217.31 today based on a price of $78.99 for VKTX at the time of writing.
<h3>Viking Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730127618_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today

<h3>Gainers</h3>
<ul>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) stock moved upwards by 22.8% to $74.16 during Thursday's regular session. The company's market cap stands at $8.2 billion. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) stock declined by 18.3% to $16.29 during Thursday's regular session. The market value of their outstanding shares is at $1.6 billion. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock fell 10.56% to $1.1. The company's market cap stands at $37.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTLA

OKYO

3 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Intraday Update

ACIC

ASTS

CBRE

Laboratory Corporation Of America Holdings

PEGA

PLXS

POOL

RKLB

TMUS

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

TSLA: 14% &#x7C; <a href="https://www.benzinga.com//node/41511367">Tesla shares are trading higher following a Q3 earnings beat.</a>
&nbsp;
VKTX: 7% &#x7C; <a href="https://www.benzinga.com//node/41514310">Viking Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.</a>
&nbsp;
ZENA: 64% &#x7C; <a href="https://www.benzinga.com//node/41513773">ZenaTech's ZenaDrone Subsidiary Acquires A US Design Patent For A Drone Design Pertaining To Drone Design Used In Its ZenaDrone 1000 Product</a>

ZENA

Market-Moving News for October 24th

Viking Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $90 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target

On Wednesday, Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)&nbsp;released its&nbsp;third-quarter sales report. Sales increased 9% year over year to 15.14 billion Swiss francs (~$17.5 billion).
The company&#8217;s pharmaceuticals division reported sales of 11.62 billion Swiss francs.
Roche&#8217;s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs.
Sales of Vabysmo, an age-related macular degeneration (AMD) treatment, <a target="_blank" href="https://assets.roche.com/f/176343/x/ad8d248346/appendix-tables-q3-2024.pdf" rel="noreferrer noopener">surged</a> 59% year over year to 1.02 billion Swiss francs.
Roche <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-10-23" rel="noreferrer noopener">reiterated</a> its business outlook, with the growth of around mid-single digits in group sales and the high-single-digit range for core earnings-per-share.
The European drugmaker <a target="_blank" href="https://assets.roche.com/f/176343/x/03b85564df/irp231024-a.pdf" rel="noreferrer noopener">axed</a> a mid-stage chronic cough program, RG6341.
Roche also axed a Phase 3 trial for divarasib in the second-line treatment of non-small cell lung cancer (NSCLC) and started a separate Phase 3 trial in NSCLC.
The company also removed Phase 2 trials for RG6416 (bepranemab) for Alzheimer&#8217;s, RG6139 tobemstomig monotherapy + combos for solid tumors, and RG7854/ RG6346/ RG6084 ruzotolimod/xalnesiran/PDL1 LNA for HBV infection.
Reuters noted that Roche is urging regulatory authorities to block Novo Holdings&#8217; proposed $16.5 billion acquisition of CDMO giant Catalent Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>), arguing that the deal would have wide-ranging negative effects on the industry.
Novo Holdings is the controlling shareholder of&nbsp;Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Last week, a coalition of unions, consumer groups, and public interest organizations wrote a letter to Lina Khan, Chair of the Federal Trade Commission (FTC), voicing strong opposition to the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41409503/after-us-senator-unions-urge-federal-trade-commission-to-block-novos-16-5b-acquisition-of-catalen" rel="noreferrer noopener">acquisition of Catalent</a>.
In the lawsuit, the coalition <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrmlxkzpe/Consumer%20and%20Union%20Letter%20on%20Novo%20Catalent-10.17.24.pdf" rel="noreferrer noopener">contended</a> that although Novo and Eli Lilly are currently the only two competitors in the GLP-1 market, several other pharmaceutical and biotech companies—such as Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), Structure Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>), Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Sun Pharma, Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Roche, and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)—have GLP-1 therapies in development.
These companies will require a CDMO partner to support the launch of their products in the coming years. Catalent is currently the only CDMO with significant experience collaborating with GLP-1 manufacturers.
Roche told Reuters that it is not directly impacted.
Reuters, citing Roche&#8217;s CEO Thomas Schinecker during a media call, highlights that limiting competition in this field would not be wise.
It adds that regulators could be making a mistake from an industry perspective. Schinecker elaborated in an analyst call that if companies start acquiring contract manufacturing organizations, market competition could decline.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41494373/whats-going-on-with-nvidia-stock-on-wednesday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Nvidia Stock On Wednesday?</a></li>
</ul>

Large Cap

Eurozone

CTLT

GPCR

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent.

Earnings

Earnings Beats

Viking Therapeutics Q3 2024 GAAP EPS $(0.22) Beats $(0.26) Estimate

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) is preparing to release its quarterly earnings on Wednesday, 2024-10-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Viking Therapeutics to report an earnings per share (EPS) of $-0.25.
Anticipation surrounds Viking Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.07, which was followed by a 28.31% increase in the share price the next day.
Here's a look at Viking Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.27</td>
<td>-0.28</td>
<td>-0.26</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.20</td>
<td>-0.26</td>
<td>-0.25</td>
<td>-0.23</td>
</tr>
<tr>
<td>Price Change %</td>
<td>28.000000000000004%</td>
<td>6.0%</td>
<td>18.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729620138_0.png" alt="eps graph" />
<h3>Market Performance of Viking Therapeutics's Stock</h3>
Shares of Viking Therapeutics were trading at $64.34 as of October 21. Over the last 52-week period, shares are up 484.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/VKTX/earnings">To track all earnings releases for Viking Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Viking Therapeutics's Earnings

Viking stock drops 13% after jumping 9% on obesity drug data

How does Viking's weight loss med compare to ones from Novo, Eli Lilly?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), 2s...

Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), 2seventy bio (TSVT)

Wall Street Breakfast Podcast: Debt Weighs On Voters On Election Day

Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on TheFly – t...

Viking Therapeutics participates in a conference call with JPMorgan

Novo Nordisk: A GLP-1 Leader Faces Increasing Competition

Viking Therapeutics ($VKTX), a player in the biopharmaceutical industry, is grabbing investors' attention after its stock has surged up over 500% i...

Viking Therapeutics (VKTX) Stock Surges on Promising Treatment Pipeline

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity

ALKS

APLS

ARVN

ASND

AZNCF

BCRX

CRBP

DERM

ELAB

NKTR

RPRX

TKPHF

TSVT

VRCA

VRNA

Small Cap

Press Releases

Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024

Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Opinion

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Comments

Viking Therapeutics

Noticias

Últimas noticias sobre Viking Therapeutics (NASDAQ:VKTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL